These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8553838)
1. High levels of aggrecan aggregate components are present in synovial fluids from human knee joints with chronic injury or osteoarthrosis. Ratcliffe A; Grelsamer RP; Kiernan H; Saed-Nejad F; Visco D Acta Orthop Scand Suppl; 1995 Oct; 266():111-5. PubMed ID: 8553838 [No Abstract] [Full Text] [Related]
2. Differential levels of synovial fluid aggrecan aggregate components in experimental osteoarthritis and joint disuse. Ratcliffe A; Beauvais PJ; Saed-Nejad F J Orthop Res; 1994 Jul; 12(4):464-73. PubMed ID: 7520485 [TBL] [Abstract][Full Text] [Related]
3. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Lohmander LS; Ionescu M; Jugessur H; Poole AR Arthritis Rheum; 1999 Mar; 42(3):534-44. PubMed ID: 10088777 [TBL] [Abstract][Full Text] [Related]
4. Topographic variation in biglycan and decorin synthesis by articular cartilage in the early stages of osteoarthritis: an experimental study in sheep. Little CB; Ghosh P; Bellenger CR J Orthop Res; 1996 May; 14(3):433-44. PubMed ID: 8676257 [TBL] [Abstract][Full Text] [Related]
5. The release of aggrecan fragments into synovial fluid after joint injury and in osteoarthritis. Lohmander LS J Rheumatol Suppl; 1995 Feb; 43():75-7. PubMed ID: 7752145 [TBL] [Abstract][Full Text] [Related]
6. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. Lark MW; Bayne EK; Flanagan J; Harper CF; Hoerrner LA; Hutchinson NI; Singer II; Donatelli SA; Weidner JR; Williams HR; Mumford RA; Lohmander LS J Clin Invest; 1997 Jul; 100(1):93-106. PubMed ID: 9202061 [TBL] [Abstract][Full Text] [Related]
7. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270 [TBL] [Abstract][Full Text] [Related]
8. Pathways of aggrecan processing in joint tissues. Implications for disease mechanism and monitoring. Sandy JD; Plaas AH; Koob TJ Acta Orthop Scand Suppl; 1995 Oct; 266():26-32. PubMed ID: 8553857 [No Abstract] [Full Text] [Related]
10. Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW; Bayne EK; Lohmander LS Acta Orthop Scand Suppl; 1995 Oct; 266():92-7. PubMed ID: 8553869 [No Abstract] [Full Text] [Related]
11. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Sandy JD; Verscharen C Biochem J; 2001 Sep; 358(Pt 3):615-26. PubMed ID: 11535123 [TBL] [Abstract][Full Text] [Related]
12. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867 [TBL] [Abstract][Full Text] [Related]
13. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Lohmander LS; Saxne T; Heinegård DK Ann Rheum Dis; 1994 Jan; 53(1):8-13. PubMed ID: 8311563 [TBL] [Abstract][Full Text] [Related]
14. Repeated intraarticular injections of triamcinolone acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid. Céleste C; Ionescu M; Robin Poole A; Laverty S J Orthop Res; 2005 May; 23(3):602-10. PubMed ID: 15885481 [TBL] [Abstract][Full Text] [Related]
15. Alterations in cartilage type-II procollagen and aggrecan contents in synovial fluid in equine osteochondrosis. Laverty S; Ionescu M; Marcoux M; Bouré L; Doizé B; Poole AR J Orthop Res; 2000 May; 18(3):399-405. PubMed ID: 10937626 [TBL] [Abstract][Full Text] [Related]
16. Enhanced concentration of COMP (cartilage oligomeric matrix protein) in osteochondral fractures from racing Thoroughbreds. Skiöldebrand E; Heinegård D; Eloranta ML; Nilsson G; Dudhia J; Sandgren B; Ekman S J Orthop Res; 2005 Jan; 23(1):156-63. PubMed ID: 15607888 [TBL] [Abstract][Full Text] [Related]
17. The pathobiology of focal lesion development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis. Squires GR; Okouneff S; Ionescu M; Poole AR Arthritis Rheum; 2003 May; 48(5):1261-70. PubMed ID: 12746899 [TBL] [Abstract][Full Text] [Related]
18. Contents and distributions of the proteoglycans decorin and biglycan in normal and osteoarthritic human articular cartilage. Poole AR; Rosenberg LC; Reiner A; Ionescu M; Bogoch E; Roughley PJ J Orthop Res; 1996 Sep; 14(5):681-9. PubMed ID: 8893759 [TBL] [Abstract][Full Text] [Related]
19. Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints. Aurich M; Squires GR; Reiner A; Mollenhauer JA; Kuettner KE; Poole AR; Cole AA Arthritis Rheum; 2005 Jan; 52(1):112-9. PubMed ID: 15641059 [TBL] [Abstract][Full Text] [Related]
20. The effects of intraarticularly injected sodium hyaluronate on levels of intact aggrecan and nitric oxide in the joint fluid of patients with knee osteoarthritis. Kobayashi K; Matsuzaka S; Yoshida Y; Miyauchi S; Wada Y; Moriya H Osteoarthritis Cartilage; 2004 Jul; 12(7):536-42. PubMed ID: 15219568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]